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Abstract 
 
In vitro lycopene is the most potent antioxidant among carotenoids. While antioxidant 
function may be relevant to health, we hypothesize that metabolites of lycopene may be 
bioactive and responsible for the beneficial effects of tomato product consumption. We 
term these metabolites “lycopenoids,” which we believe may be produced from 
carotenoid monooxygenase (CMO) II, paralleling the production of retinoids from β-
carotene by CMO I. We present evidence suggesting that tomato carotenoid metabolites 
may be responsible for the reduced risk of prostate cancer seen in men consuming high 
levels of tomato products. Finally, we identify gaps in knowledge in this evolving area of 
carotenoid research. 
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Intro 
 
The red-pigmented carotenoid, lycopene, has garnered a great deal of interest as a 
bioactive compound that may help prevent chronic disease. A question for a number of 
years has been whether lycopene itself, or its metabolites or oxidation products, are 
responsible for the effects noted in various studies. In this paper we will focus on 
reviewing evidence to support the hypothesis that metabolites of lycopene, and other 
tomato carotenoids, are responsible for the bioactivity associated with higher intakes of 
tomato products. We coined a term for these lycopene metabolites, “lycopenoids,” 
because we believe these compounds are produced by an initial cleavage by carotenoid 
monooxygenase (CMO) II in a manner similar to how retinoids (retinal, retinol, and 
retinoic acid) are produced from the initial cleavage of β-carotene by CMO I (See Figure 
1). In addition to lycopene, tomatoes contain significant amounts of the carotenoids 
phytoene and phytofluene [1]. We propose that “phytoenoids” and “phytofluenoids” may 
also be produced by an initial cleavage by CMO II.  
 
Background 
 
Lycopene is a potent antioxidant in vitro, but its role in health may be due to its 
bioactive metabolites. While there is interest in lycopene and cardiovascular disease, 
skin, and eye health, the majority of research has focused on prostate cancer. Many  
epidemiological studies have found that higher intakes of tomato and tomato product 
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consumption are associated with a reduced risk of prostate cancer [2, 3]. In addition, 
intake and serum levels of lycopene have also been inversely related to prostate cancer 
occurrence [2]. Therefore, many scientists have attributed the protective effect of 
tomatoes to lycopene because it is the carotenoid found in the highest concentration in 
tomato products. While tomatoes provide 85% of the lycopene in the diet, it is also found 
in watermelon, pink grapefruit, guava, and rosehip [4]. 
 Despite epidemiological and small clinical trial evidence suggesting a possible 
protective effect of lycopene, the mechanism of action is still unclear [5-7]. Multiple 
studies have suggested that lycopene is bioactive in vivo and in vitro against prostate and 
other cancers [8-14]. For example, feeding lycopene altered expression levels of enzymes 
involved in androgen metabolism in both normal prostates and Dunning MatLyLu 
prostate tumors [15, 16]. Androgens are critical to the growth of prostate tumors, thus, 
these alterations could possibly explain the association between lycopene intake and 
reduced risk of prostate cancer. 
For reasons that are not clear, lycopene preferentially accumulates in androgen-
sensitive tissues such as the prostate [17]. When rats were fed diets containing tomato 
powder, the biodistribution of phytoene, phytofluene, and lycopene differed in various 
tissues. Interestingly, lycopene accumulated in higher amounts in the prostate even if 
tomato powder-fed animals received an oral dose of phytoene or phytofluene prior to 
study termination (unpublished data). Lycopene is the predominant carotenoid found in 
the prostate and its levels were significantly higher in malignant than in benign prostates 
[18]. Furthermore, in food lycopene is predominately found in the all-trans form, 
however, the prostate accumulated primarily cis-isomers of lycopene [18]. This can be 
explained by a study in ferrets that demonstrated that cis-isomers of lycopene are more 
bioavailable than the all-trans form [19]. 
There also appears to be differential tissue metabolism or accumulation of 14C 
lycopene in rats prefed lycopene. Liver and the androgen-sensitive seminal vesicles, 
accumulated about 20% of radiolabeled lycopene dose as polar products. In contrast, the 
dorsolateral prostate, the region of the rat prostate most homologous to the peripheral 
region where men develop prostate cancer, accumulated up to 80% of the radiolabeled 
dose as polar products of lycopene [20]. We believe these polar products are lycopene 
metabolites and oxidation products that have yet to be identified. Further research 
determined that whether or not lycopene was prefed did not alter the amounts of polar 
products that accumulated in the prostate of rats after receiving a 14C lycopene dose [21]. 
These studies together indicate that prostate tissue metabolizes or preferentially 
accumulates these polar lycopene products. 
 
Candidate Cleavage Enzymes 
 
 The enzymes most likely responsible for the initial metabolism of lycopene are 
the two main mammalian carotenoid cleaving enzymes, CMO I and II. It is generally 
accepted that CMO I cleaves β-carotene centrally to form two molecules of retinal, while 
CMO II eccentrically cleaves β-carotene to form β-apo carotenals, which can then form 
retinoic acid after undergoing β-oxidation-like reactions (Figure 1). However, little is 
known about the in vivo action of CMO I & II on other carotenoids such as lycopene, 
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phytoene, and phytofluene. For lycopene, the products would theoretically be 
acycloretinal or apo-lycopenals for CMO I and II, respectively.  
E. coli engineered to produce lycopene and express mouse CMO I exhibited color 
bleaching suggesting that CMO I cleaved lycopene [22].  However, when lycopene was 
provided at levels equivalent to β-carotene to purified recombinant mouse CMO I, no 
acycloretinal was detected. Lycopene levels had to be increased 2.5-3 fold higher than β-
carotene to even detect this product. Similarly, recombinant human CMO I was found to 
have little or no activity towards lycopene and zeaxanthin, but did cleave the provitamin 
A carotenoids β-carotene and β-cryptoxanthin [23]. Therefore, these studies suggest that 
lycopene is a poor substrate for CMO I. 
Due to its similarity to retinoic acid, several in vitro studies have examined the 
bioactivity of the potential CMO I lycopene cleavage product acycloretinoic acid. 
Acycloretinoic acid activated the retinoic acid receptor element in human mammary 
MCF-7 cells, however this effect was approximately 100-fold less potent than retinoic 
acid itself [24]. Like lycopene, acycloretinoic acid was able to stimulate gap junction 
communication in human fetal skin fibroblasts, but a 10-fold higher concentration was 
needed to be as effective as lycopene itself [25]. In further in vitro work, acycloretinoic 
acid reduced the viability of human prostate cancer cell lines and increased apoptosis, 
however, supraphysiological levels were required to generate these effects [26]. Based on 
low production and bioactivity, we hypothesize that central cleavage of lycopene by 
CMO I to form acycloretinal or acycloretinoic acid is not likely a candidate to explain the 
anticancer effects of lycopene. 
Compared to CMO I, CMO II has been far less studied. E. coli engineered to 
produce lycopene and expressing mouse CMO II exhibited a color shift indicating that 
lycopene was cleaved. This was in contrast to E. coli engineered to produce β-carotene 
and express CMO II, which did not display a color shift [27]. We have recently 
completed a pilot study with CMO I knockout mice. In CMO I knockout mice and 
control mice fed lycopene, there were no differences in serum lycopene levels, however 
hepatic lycopene levels were approximately 5-fold lower in CMO I knockout mice 
(unpublished data). Previous work in another laboratory found that there was an 
approximate 4-fold increase in hepatic CMO-II mRNA expression levels in CMO I 
knockout mice compared to control (personal communication). Therefore, we believe the 
increase in hepatic CMO II levels in CMO I KO mice leads to increased cleavage of 
lycopene to lycopenoids, resulting in lower hepatic lycopene levels. Recently, the 
laboratory of Wang cloned the ferret CMO II gene and expressed it in Spodoptera 
frugiperda 9 cells. When they exposed cells to mixtures of lycopene isomers they found 
evidence suggesting that cis-isomers of lycopene may be preferred substrates of CMO II 
compared to the parent all-trans lycopene or β-carotene [28]. 
In addition to CMO II, it is also possible that cytochrome P450 enzymes are 
involved in the cleavage of lycopene, phytoene, and phytofluene, but this is most likely to 
occur with high intakes of carotenoids. There appears to be a differential effect of 
carotenoids on inducing P450 enzymes. Ten μM of β-carotene or β-apo-carotenals has 
been found to induce the pregnane X receptor (PXR) reporter gene in HepG2 cells [29]. 
PXR induces the expression of cytochrome P450 enzymes such as CYP3A4, which is 
estimated to be responsible for approximately 60% of xenobiotic metabolism in humans 
[30]. However, unlike β-carotene, lycopene was found to have no effect on PXR levels 
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[29]. This finding does not mean that lycopene is not potentially metabolized by 
cytochrome P450 enzymes, but it does not appear to induce them to the same extent as β-
carotene. The effects of lycopene on P450 activity in vivo are still in need of clarification. 
It has been reported that P450 enzyme activity was induced in female rats receiving 
lycopene by gavage for 2 weeks [31]. However, feeding tomato powder to male hamsters 
led to a decrease in P450 enzyme activity, while feeding lycopene to male rats had no 
effect on P450 activity [32, 33]. Whether the difference in these studies is due to the 
difference in sex of the animals, administration versus feeding, or other methodology 
issues has not been resolved. 
In addition, there is in vitro evidence that lycopene is cleaved by soybean 
lipoxygenase [34, 35]. However, a recent molecular modeling study found that lycopene 
actually bound to the putative allosteric site of 5-lipoxygenase and not in the cleavage 
site. In contrast, the lycopene metabolites, 4-methyl-8-oxo-2,4,6-nonatrienal and 2,7,11-
trimethyl-tetradecahexaene-1,14-dial, bound to the catalytic site of the enzyme [36]. 
There is little known about whether lycopene or carotenoids alter the expression or 
activity of 5-lipoxygenase. 
 
Metabolic Products Identified 
 
 To our knowledge, the first in vivo lycopene metabolite reported was 5,6-
dihydroxy-5,6-dihydrolycopene in human serum by Khachik and colleagues. The 
authors’ hypothesized that this metabolite resulted from oxidation of lycopene to form 
lycopene 5,6-epoxide which then was metabolically reduced to 5,6-dihydroxy-5,6-
dihydrolycopene [37-39]. This same lab also identified epimeric 2,6-cyclolycopene-1,5-
diols in human serum and milk, which they hypothesized were produced in a similar 
fashion as 5,6-dihydroxy-5,6-dihydrolycopene [40]. In preruminant calf serum, Sicilia et 
al. reported the lycopene metabolites 5,6-dihyrolycopene, 5,6-dihydro-5-cis-lycopene, 
and tetrahydrolycopene of which the exact position of the hydrogenation could not be 
determined [41]. 
In the liver of F344 rats fed lycopene, we identified apo-8’-lycopenal and 
potentially apo-12’-lycopenal as metabolites of lycopene (See Figure 1). In addition, 
there are a number of other polar products that have yet to be identified [42]. Similar 
work has been done in the ferret lung [28]. However, only apo-10’-lycopenol was 
reported, a product not found in rat liver [42]. The cause of these metabolite differences 
in the last two studies, be it species, tissue, or methodology differences should be 
elucidated. 
 There have been a number of studies looking at formation of lycopene metabolites 
and oxidation products in vitro[34, 43-46]. We will only discuss two studies due to space 
constraints. Incubation of lycopene in toluene, aqueous Tween 40, or liposomal 
suspension under atmospheric oxygen at 37°C for 72 hours led to identification of 8 
products 3,7,11-trimethyl-2,4,6,10-dodecapentaen-1-al, 6,10,14, trimethyl-3,5,7,9,13-
pentadecapentaen-2-one, acycloretinal, apo-14’-lycopenal, apo-12’-lycopenal, apo-10’-
lycopenal, apo-8’-lycopenal, and apo-6’-lycopenal [43]. Two cleavage products and 4 
oxidation products were identified from the incubation of deuterated lycopene with the 
postmitochondrial fraction of rat intestinal mucosa and soybean lipoxygenase. The 
cleavage products were 3-keto-apo-13-lycopenone and 3,4-dehydro-5,6-dihydro-15-apo-
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lycopenal, while the oxidative metabolites were: 2-ene-5,8-lycopenal-furanoxide, 
lycopene-5, 6,5',6'-diepoxide, lycopene-5,8-furanoxide isomer, 3-keto-lycopene-5',8'-
furanoxide [34]. Since some of the products produced in these in vitro systems have not 
been found in vivo, it remains to be sorted out whether they are relevant in vivo. 
 
Antioxidant Function vs. Lycopenoid Bioactivity 
 
Antioxidant function is the main mechanism through which lycopene has been 
thought to decrease chronic disease risk. For example, lycopene acting as an antioxidant 
can prevent DNA damage, which leads to mutations that cause cells to become 
cancerous. Lycopene is a potent in vitro antioxidant, being 2-fold and 10-fold more 
efficient at quenching singlet oxygen than β-carotene and α-tocopherol, respectively [47]. 
However, Freeman et al. found the human prostate concentration of α-tocopherol to be 
162-fold higher than lycopene [48]. Therefore, even with reduced antioxidant potential, 
the much higher concentration of α-tocopherol in this tissue suggests that it is unlikely 
that lycopene itself plays a major role as an antioxidant. In in vitro experiments, not 
changing lycopene-containing media during the 3-day treatment period was significantly 
more effective in reducing proliferation of connexin 43 wild-type mouse embryonic 
fibroblasts, compared to changing the lycopene treatment and media daily (unpublished 
data). We believe that not changing the media allows for the build up of lycopene 
metabolites and oxidation products, thus leading to the more effective antiproliferative 
response. Taken together, these findings provide support to our hypothesis that 
lycopenoids are the compounds responsible for lycopene’s antiproliferative activity. 
In contrast to the findings with acycloretinoic acid, some lycopene metabolites 
and oxidation products have been found to be bioactive. Apo-10 lycopenoic acid was 
found to decrease the proliferation of non-small cell lung cancer cells in vitro (personal 
communication). An ethanolic extract containing lycopene metabolites and oxidation 
products was as effective as lycopene itself in transactivating antioxidant response 
element (ARE) genes [49]. Furthermore, the lycopene oxidation product, 2,7,11-
trimethyl-tetradecahexaene-1,14-dial, enhanced gap junction communication in rat liver 
epithelial WB-F344 cells [45]. Lastly, both lycopene or phytofluene metabolites inhibited 
the growth of HL-60 human promyelocytic leukemia cells [50]. 
 
Are Tissue Levels of Lycopenoids High Enough To Produce Biological Effects? 
 
The levels of lycopenoids in tissues appear to be equivalent or greater than the 
levels of retinoic acid. In rat liver, retinoic acid levels have been reported to be 11.3 
pmol/g tissue, while we estimated the levels of apo-8’ lycopenal to be ~600 pmol/g [42, 
51]. In ferret lung, retinoic acid has been reported to be 17 pmol/g, while the levels 
reported of apo-10-lycopenol were 8 pmol/g [28, 52]. Due to their structural and polarity 
similarities to retinoic acid, we believe that lycopenoids may be agonist or antagonists for 
nuclear receptors such as RARs/RXRs/LXR/PXR/PPARs or activate response elements 
such as the ARE. For instance, we recently found that lycopene feeding caused a 
significant downregulation of PPARγ in rat kidney and adrenal and the PPARγ target 
gene fatty acid binding protein 3 (FABP3) [33].  
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Future Directions  
 
 There is a great deal we do not know about lycopene metabolism and the 
metabolic effects of lycopenoids. Identification, particularly in vivo, of metabolites and 
oxidation products is still an active area of investigation. In addition, further clarification 
is needed to determine which lycopenoids are produced enzymatically and 
nonenzymatically, as well as in what tissues they are produced and accumulate. If CMO 
II is indeed the key enzyme in the metabolism of lycopene, is this enzyme specific for 
lycopene, or does it have a broad specificity for a variety of carotenoids? For instance, it 
may be that CMO I cleaves provitamin A carotenoids, while CMO II is more active 
towards nonprovitamin A carotenoids. A further understanding is needed of the effects of 
levels and timing of a carotenoid dose on the production of metabolites and the resulting 
biological effects. For example, consumption of tomato powder, lycopene, or phytofluene 
for 4 days to 8-week old Fisher 344 rats led to a significant reduction in serum 
testosterone levels [53]. This is clearly an acute effect, as previously feeding tomato 
powder or lycopene for weeks or months did not affect serum testosterone levels [54 & 
unpublished data]. However, even acute decreases in androgens could potentially help to 
reduce the risk of developing prostate cancer. Furthermore, we know little about the 
differential effects of carotenoids lycopene, phytoene, phytofluene and β-carotene on 
metabolism and gene expression. Lastly an understanding of the potential synergistic or 
additive effect among tomato carotenoids may explain why whole food sources are more 
effective than single carotenoid supplements. For example, tomato powder consumption 
is more effective than lycopene alone in preventing the development of and progression 
of prostate cancer in rats [55 & unpublished data]. Overall, future research will continue 
to clarify the role of lycopene, tomato carotenoids, and their metabolites in producing the 
beneficial effects associated with tomato intake. 
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Figure 1 Legend 
 
Proposed Metabolism of Tomato Carotenoids. The main metabolic pathway for β-
carotene is central cleavage by CMO I to form retinal which can be reduced to retinol. 
Retinoic acid can be formed by the oxidation of retinal or retinol, or alternatively it is 
believed that CMO II eccentrically cleaves β-carotene to form β-apo carotenals. The β-
apo carotenals can then undergo β-oxidation to eventually form retinoic acid. We believe 
lycopene cleavage by CMO II to lycopenoids parallels retinoid production from β-
carotene by CMO I. Due to their similarity in structure, we believe that phytoene and 
phytofluene may also be cleaved like lycopene by CMO II to form phytoenoids and 
phytofluenoids.
11 
 
